Previous 10 | Next 10 |
Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER Study PR Newswire Second largest study to date in COVID-19 outpatients (N=1,936) Highly superior c...
Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 TOGETHER Study Results of Peginterferon Lambda for COVID-19 on Thursday, March 17, 2022 PR Newswire Live Conference Call and Webcast at 5:30 AM Pacific / 8:30 AM Eastern PALO ALTO, Cali...
Update: 3:49 p.m. ET: Fitch has dropped its rating on Dutch-based telecom Veon (NASDAQ:VEON) down to junk status due to the company’s heavy exposure to Russia and Ukraine. Standard & Poor’s also cut Veon’s rating further into junk territory. Update 3:21 p.m. ET: ...
Update 3:21 p.m. ET: Citigroup (NYSE:C) announced that it’s expanding plans to exit Russia. The banking giant previously disclosed that it would be winding down its Russian consumer business due to the Ukraine War, but said Monday that it will also review exiting other business li...
Update 1:16 p.m. ET: The U.S. has told its allies that China has signaled a willingness to provide military assistance to Russia to support its invasion of Ukraine, the FT reported, citing officials familiar with diplomatic cables. Update 12:08 p.m. ET: "The war in Ukraine has already ca...
Update 12:08 p.m. ET: "The war in Ukraine has already caused a terrible human toll," the BlackRock Investment Institute said in a note. "We see it extracting a heavy economic price as well, mostly via higher energy costs. This is a major supply shock layered onto an existing one, and we ...
Update 11:56 a.m. ET: A Ukrainian negotiator says that peace talks with Russia have been paused until Tuesday. Update 11:51 a.m. ET: Eiger (NASDAQ:EIGR) extends gains with no impact to trials in Russia and Ukraine. Update 10:48 a.m. ET: Commodity ETFs moderate after spikes. Talks between...
The shares of the commercial-stage biopharmaceutical company, Eiger BioPharmaceuticals (EIGR +8.9%) are approaching the highest level in nearly three months as investors react to the updates on its clinical trials in Russia and Ukraine. Despite worse than expected financials, Eiger (NASDAQ:EI...
The following slide deck was published by Eiger BioPharmaceuticals, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Eiger BioPharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation
Eiger BioPharmaceuticals, Inc. (EIGR) Q4 2021 Earnings Conference Call March 10, 2022 4:30 P.M. ET Company Participants Sri Ryali - Chief Financial Officer David Cory - President and Chief Executive Officer Ingrid Choong - Senior Vice President-Clinical Development Eldon Mayer - Chief Commerc...
News, Short Squeeze, Breakout and More Instantly...
Eiger BioPharmaceuticals Inc. Company Name:
EIGR Stock Symbol:
NASDAQ Market:
Eiger BioPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today ...